Literature DB >> 22778808

ACS chemical neuroscience molecule spotlight on Lorcaserin.

Corey R Hopkins1.   

Abstract

Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2C) (5-HT(2C)) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

Entities:  

Keywords:  Lorcaserin; selective serotonin 5-HT2C receptor agonist; weight loss

Mesh：

Substances：

Year:  2010        PMID： 22778808      PMCID： PMC3368635          DOI： 10.1021/cn100059u

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  2 in total

1.  Prevalence and trends in obesity among US adults, 1999-2008.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Lester R Curtin
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

2.  Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Authors:  William J Thomsen; Andrew J Grottick; Frederique Menzaghi; Hazel Reyes-Saldana; Stephen Espitia; Diane Yuskin; Kevin Whelan; Michael Martin; Michael Morgan; Weichao Chen; Hussien Al-Shamma; Brian Smith; Derek Chalmers; Dominic Behan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030
  2 in total
  1 in total

1.  Lorcaserin for the treatment of obesity? A closer look at its side effects.

Authors:  James J DiNicolantonio; Subhankar Chatterjee; James H O'Keefe; Pascal Meier
Journal:  Open Heart       Date:  2014-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.